The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Argos Therapeutics; Bayer; Genentech; Merck; Novartis; Pfizer; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Onyx (Inst)
Other Relationship - Boehringer Ingelheim
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; Novartis; pfizer
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Naomi B. Haas
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals (I)
Expert Testimony - Lilly (I)
 
Sabina Signoretti
No Relationships to Disclose
 
Richard B. Lanman
Employment - Guardant Health; Veracyte
Leadership - Guardant Health
Stock and Other Ownership Interests - Guardant Health; Veracyte
Research Funding - Guardant Health
 
Kimberly Banks
Employment - Guardant Health
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)